Abstract
In 2015, more than 530 000 people were prescribed statins in Norway. Adverse effects from the musculoskeletal system as well as less specific side effects are frequently reported. The extent of these contrasts with observations made in randomised controlled studies which report the prevalence of such adverse effects as being in line with placebo. Breaks from drug treatment, low doses, switching medication and use of other lipid-lowering drugs are the most relevant approaches to dealing with adverse effects.
MeSH terms
-
Biological Products / administration & dosage
-
Biological Products / therapeutic use
-
Ezetimibe / administration & dosage
-
Ezetimibe / therapeutic use
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Hypolipidemic Agents / administration & dosage
-
Hypolipidemic Agents / therapeutic use
-
Muscular Diseases / chemically induced*
-
Muscular Diseases / diagnosis
-
Muscular Diseases / drug therapy
-
PCSK9 Inhibitors
-
Risk Factors
Substances
-
Biological Products
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypolipidemic Agents
-
PCSK9 Inhibitors
-
red yeast rice
-
PCSK9 protein, human
-
Ezetimibe